Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women

Eur J Gynaecol Oncol. 2008;29(6):594-7.

Abstract

Objectives: The aim of this work was to compare concentrations of adiponectin in the serum of obese women with endometrial cancer, endometrial hyperplasia with atypia, and normal endometrium.

Methods: We enrolled 105 obese women treated at the Department of Gynecological Surgery and Oncology of Adults and Adolescents. The patients were allocated to groups depending on the histological diagnosis (R - endometrial cancer, P - polyps, K - normal endometrium). We subdivided group R depending on the stage and grade of cancer.

Results: Significantly lower concentrations of adiponectin were found in patients with endometrial cancer (mean 15.28 microg/ml) as compared with polyps (29.94 microg/ml, p < 0.001) or normal endometrium (22.7 microg/ml, p < 0.05). Stage of cancer had no significant effect on the adiponectin level. When cancer grade was compared, lower levels of adiponectin were observed in patients with G3 (12.86 microg/ml) than G1 (19.04 microg/ml, p < 0.05).

Conclusion: Reduced levels of adiponectin may represent an independent risk factor for endometrial cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood*
  • Case-Control Studies
  • Endometrial Hyperplasia / blood*
  • Endometrial Hyperplasia / complications
  • Endometrial Hyperplasia / pathology
  • Endometrial Neoplasms / blood*
  • Endometrial Neoplasms / complications
  • Endometrial Neoplasms / pathology
  • Female
  • Humans
  • Obesity / blood*
  • Obesity / complications

Substances

  • Adiponectin